Skip to main content

Sugammadex versus neostigmine in adults aged 60 years and older undergoing surgery: a systematic review and meta-analysis of postoperative recovery and clinical outcomes

In brief

Sugammadex was linked to 66% less residual paralysis in older surgical patients

Across eight randomized trials involving 851 adults aged 60 and older, sugammadex was associated with a lower risk of residual neuromuscular blockade and about 9 minutes less time in recovery. Apparent reductions in low oxygen levels and hospital stay did not remain statistically significant after an adjusted analysis, and the paralysis finding varied across studies.

Journal
Anaesthesia, critical care & pain medicine (Q1)
Published
16 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Edison Vitório de Souza Júnior, Gleisy Kelly Neves Gonçalves, Diego Pires Cruz, Diego Alcântara Alves, Randson Souza Rosa, Namie Okino Sawada
PMID
43039077
DOI
10.1016/j.accpm.2026.101996

Why clinicians should know about it

  • Picked for Anesthesiology and Pain Medicine (paper of the day, 19 November 2026): Meta-analysis compares neuromuscular reversal and postoperative recovery outcomes

Abstract

BACKGROUND: Uncertainty remains regarding the clinical advantages of sugammadex over neostigmine in older adults, particularly for recovery efficiency and postoperative outcomes. AIM: To compare the effects of sugammadex versus neostigmine on postoperative recovery and clinical outcomes in adults aged 60 years and older undergoing surgery. METHODS: This systematic review and meta-analysis included eight randomized controlled trials. The primary outcome was postoperative residual neuromuscular blockade (PRNB). Secondary outcomes included post-anesthesia care unit (PACU) length of stay, hospital length of stay, time to extubation, hypoxemia, pneumonia, and postoperative nausea and vomiting (PONV). Effect measures were risk ratio and mean difference. RESULTS: A total of 851 participants were included, and 50.2% received sugammadex. Sugammadex was associated with a lower risk of PRNB (RR 0.34 [95% CI: 0.18; 0.64]; p <  0.001; I² = 54%), with moderate between-study heterogeneity; however, the 95% prediction interval (0.11; 1.03) included the null value. Sugammadex significantly reduced PACU length of stay (MD -8.84 [95% CI: -12.18; -5.51], p <  0.001, I2 = 0%), hospital length of stay (MD -1.12 [95% CI: -2.01; -0.24], p <  0.01, I2 = 16%), and hypoxemia (RR = 0.61 [95% CI: 0.38; 0.97]; p =  0.04, I2 = 0%). No statistically significant differences were observed for the remaining outcomes. CONCLUSION: Sugammadex was associated with a lower risk of PRNB and shorter PACU stays compared with neostigmine. Although the primary analyses suggested reductions in hypoxemia and hospital length of stay, these associations were not statistically significant after the Hartung-Knapp adjustment. INTERNATIONAL PROSPECTIVE REGISTER OF SYSTEMATIC REVIEWS (PROSPERO): CRD420261376045.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.